NDAOPHTHALMICFOR SUSPENSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Just now · AI intelligence enriched Just now
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYCETIN HYDROCORTISONE is a fixed-dose ophthalmic suspension combining chloramphenicol (a broad-spectrum antibiotic) and hydrocortisone acetate (a corticosteroid) for topical eye use. This combination addresses bacterial eye infections with concurrent inflammation, leveraging chloramphenicol's potent gram-positive and gram-negative coverage alongside anti-inflammatory action. The product targets patients requiring dual antimicrobial and steroid therapy in acute or chronic ocular conditions.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30%) signals shrinking team focus and shift toward lifecycle management rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's LOE-approaching status and minimal growth trajectory, indicating limited hiring expansion in traditional commercial roles. Career advancement on this asset is constrained; professionals should anticipate eventual transition to newer portfolios as brand focus shifts.
Brand ManagerField Sales Representative
Worked on CHLOROMYCETIN HYDROCORTISONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.